HRS-7535 vs regor GLP-1

NCT06904105 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial (n=556). The primary endpoint, percent weight change at week 44, was met: participants lost 9.5% (120 mg) and 10.9% (180 mg) of body weight versus 2.5% with placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT06867718 · Phase 2 · completed

The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.

NCT06672172 · Phase 3 · completed

This is a well-designed randomized, double-blind, placebo-controlled trial with a recognized clinical measure (HbA1c change) as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.